Sanofi unveils positive Lemtrada data as it awaits FDA approval; Aspen looking to continue its deal streak;

@FiercePharma: Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients. News | Follow @FiercePharma

@EricPFierce: Merck & Co is again shipping BCG vaccine but Sanofi is not. Story | Follow @EricPFierce

@CarlyHFierce: FDA approves Sanofi's Menactra as meningococcal booster. More | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) is trying again to move some Paxil birth defect lawsuits to federal court from a state court in Delaware. Report

> As it awaits FDA approval for MS med Lemtrada, Sanofi ($SNY) has unveiled data on the drug that show lasting benefits. Release

> Riding high on deals with Glaxo ($GSK) and Merck ($MRK), South Africa's Aspen is now seeking further acquisitions. Report

> The FDA is inspecting the Gujarat, India, plant of Sun Pharma's U.S. subsidiary, Caraco Pharmaceutical Laboratories. More

> Opioid abuse-fighters are aiming to combat the problem with continuing medical education. More

Medical Device News

@FierceMedDev: Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: ACLA head makes case against FDA LDT regulation to Congress. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Top Senate Democrats unveil plans to curb corporate tax inversions. Reuters story | Follow @EmilyWFierce

> Harvard gets DARPA grant to develop soft, mobility exosuit. More

> Blackberry to integrate medical devices in India. Article

> Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Story

Biotech News

@FierceBiotech: Gates Foundation adds $50M to help speed Ebola drug development efforts. Story | Follow @FierceBiotech

@JohnCFierce: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets - via @TracyStaton. Article | Follow @JohnCFierce

@DamianFierce: Biotech's sprawling PED scandal widens as @adamfeuerstein admits that he "juices" daily. Report | Follow @DamianFierce

@EmilyMFierce: Uh oh. Survival rate of Ebola may be less than what we think. More from Science | Follow @EmilyMFierce

> Baxalta: Baxter's newly named biopharma spinout has had its ups and downs. Article

> Virobay tees up a $50M IPO to get a trio of candidates into Phase II. More

> Sanofi keeps the faith in MS and eyes a new dawn for Genzyme. News

Vaccines News

> Glaxo's Ebola vaccine passes key animal test as human trials begin. News

> Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients. More

> New problems at GSK flu vaccine plant will impact U.S., Canada orders. Story

> Takeda on track for dengue vaccine nods in 2017-18. Article

> FDA approves Sanofi's Menactra as meningococcal booster. Item

Pharma Manufacturing News

> Apotex recalls Paxil tainted at GSK plant. Story

> Sources: FDA inspectors in Sun plant that has had recalls. More

> FDA fight with compounder tests its patience and its limits. Article

> Hospira will prep Indian workers at Vizag 'university.' Story

> Merck again shipping BCG cancer treatment but Sanofi still is not. Report

And Finally... In a randomized trial, Insulin degludec given once daily proved noninferior to insulin detemir in children and adolescents with Type 1 diabetes. Report

Suggested Articles

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.

Novartis is rolling out head-to-head data for its MS drug in advance of an expected FDA approval next month, but competition will still be tough.

The FDA knocked Altaire Pharmaceuticals for falsified data and harebrained contraptions at its New York plant in a scathing warning letter.